Other equities research analysts have also issued reports about the company. Zacks Investment Research upgraded INmune Bio from a “hold” rating to a “buy” rating and set a $7.50 target price for the company in a report on Friday, May 13th. Maxim Group started coverage on shares of INmune Bio in a report on Friday, May 6th. They set a “buy” rating and a $22.00 price target for the company.
NASDAQ:INMB opened at $7.27 on Tuesday. The company has a market capitalization of $130.47 million, a P/E ratio of -3.77 and a beta of 2.44. The stock’s 50 day moving average price is $7.80 and its 200 day moving average price is $9.52. The company has a debt-to-equity ratio of 0.19, a quick ratio of 23.89 and a current ratio of 23.89. INmune Bio has a 52 week low of $6.18 and a 52 week high of $30.37.
A number of hedge funds have recently modified their holdings of the stock. Morgan Stanley lifted its holdings in INmune Bio by 97.4% during the 1st quarter. Morgan Stanley now owns 3,093 shares of the company’s stock valued at $37,000 after purchasing an additional 1,526 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in INmune Bio during the 3rd quarter valued at $31,000. Fermata Advisors LLC raised its position in INmune Bio by 9.1% in the 1st quarter. Fermata Advisors LLC now owns 19,586 shares of the company’s stock valued at $165,000 after purchasing an additional 1,631 shares during the last quarter. Bank of America Corp DE boosted its stake in INmune Bio by 109.5% in the fourth quarter. Bank of America Corp DE now owns 3,769 shares of the company’s stock worth $38,000 after purchasing an additional 1,970 shares in the last quarter. Finally, State Street Corp lifted its position in INmune Bio by 11.4% during the 1st quarter. State Street Corp now owns 37,663 shares of the company’s stock worth $317,000 after buying an additional 3,847 shares in the last quarter. 13.91% of the stock is owned by hedge funds and other institutional investors.
INmune Bio Company Profile (Get Rating)
INmune Bio, Inc, a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease.
- Get a free copy of the StockNews.com research report on INmune Bio (INMB)
- CrowdStrike: A Cybersecurity Unicorn
- Texas Roadhouse Stock Looks Sizzling Down Here
- Two Stocks You Shouldn’t Buy On Post-Earnings Weakness
- Time to Bid Low for Farfetch Stock
- Don’t Wait Too Long to Buy These 3 Mega Caps
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.